Wall Street Zen Upgrades Henry Schein (NASDAQ:HSIC) to Buy

Henry Schein (NASDAQ:HSICGet Free Report) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Several other research firms have also recently issued reports on HSIC. Evercore ISI increased their target price on Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday. Leerink Partners set a $75.00 price target on Henry Schein in a report on Monday, July 14th. Stifel Nicolaus reaffirmed a “hold” rating and set a $75.00 price objective (down from $80.00) on shares of Henry Schein in a research report on Friday, July 25th. Baird R W downgraded Henry Schein from a “strong-buy” rating to a “hold” rating in a report on Monday, July 14th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Henry Schein in a research report on Friday, October 31st. Five equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $76.08.

Read Our Latest Stock Analysis on Henry Schein

Henry Schein Stock Performance

Shares of Henry Schein stock opened at $71.90 on Friday. Henry Schein has a 1 year low of $60.56 and a 1 year high of $82.49. The firm’s 50-day moving average is $66.30 and its 200 day moving average is $68.71. The stock has a market cap of $8.72 billion, a price-to-earnings ratio of 23.19, a PEG ratio of 2.06 and a beta of 0.84. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78.

Henry Schein (NASDAQ:HSICGet Free Report) last issued its earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.11. The business had revenue of $3.34 billion during the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Sell-side analysts anticipate that Henry Schein will post 4.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Henry Schein

Large investors have recently made changes to their positions in the company. Artisan Partners Limited Partnership increased its position in shares of Henry Schein by 0.9% during the 2nd quarter. Artisan Partners Limited Partnership now owns 6,462,204 shares of the company’s stock valued at $472,064,000 after purchasing an additional 55,653 shares during the last quarter. JPMorgan Chase & Co. grew its position in Henry Schein by 6.5% during the first quarter. JPMorgan Chase & Co. now owns 6,373,036 shares of the company’s stock valued at $436,489,000 after buying an additional 390,399 shares during the period. Ameriprise Financial Inc. grew its position in Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after buying an additional 2,199,695 shares during the period. Dimensional Fund Advisors LP increased its holdings in Henry Schein by 4.8% during the first quarter. Dimensional Fund Advisors LP now owns 2,240,933 shares of the company’s stock valued at $153,480,000 after buying an additional 103,384 shares during the last quarter. Finally, Burgundy Asset Management Ltd. raised its position in Henry Schein by 33.9% in the first quarter. Burgundy Asset Management Ltd. now owns 2,235,429 shares of the company’s stock worth $153,105,000 after acquiring an additional 566,530 shares during the period. 96.62% of the stock is currently owned by institutional investors.

About Henry Schein

(Get Free Report)

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

See Also

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.